# A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR

> **NCT00368069** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 158 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Keppra® extended release formulation - XR
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00368069
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2020-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00368069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00368069, "A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00368069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*